Scottish university reveals multimillion-pound Parkinson’s research partnership

News

Author: Roisin McCormackPublished: 10 July 2019

Prep: Cook: Serves:

Doctor analysing patient brain scan results

The University of Dundee, UK, has announced a collaboration with South Korean pharmaceutical company Bukwang to develop a new treatment for Parkinson’s.

Collaborating with researchers at the University of Oxford, UK, the university’s drug discovery unit (DDU) has found molecules that may reduce levels of a protein closely connected to the development of the condition.

The new partnership will build on this existing relationship between the universities – and facilitate a further three-year Parkinson’s research programme which will move the molecules towards clinical development.

Professor Paul Wyatt, head of the DDU, said: “Drug discovery for neurological disorders is especially challenging and an area where academia and industry need to be working together.

“This project brings together the clinical and translational research expertise in Oxford with Dundee’s professional drug-discovery capabilities, allowing us to move one stage further towards a treatment.”

To read more on this topic click here.

Acupuncture may alleviate Parkinson’s symptoms

Last Month

Next Month

Go Back

Share this story

Comments

Resources & Tools

New Parkinson’s app tracks symptoms

A new app has been developed to track Parkinson’s symptoms

“We want the world to walk with us,” says Parkinson’s Unity Walk leader

2016 Parkinson’s Unity Walk hopes to raise more than US$1.7m

The huge potential of nanotechnology on new Parkinson’s treatments

Can tiny mesh electronics revolutionise Parkinson’s treatments?

Smartphone test predicts development of Parkinson’s symptoms, study says

Researchers have created a smartphone test that may be able to predict the development of Parkinson’s symptoms. The study – carried out by researchers from the University of Oxford and funded by the Monument Trust Discovery Award from charity Parkinson’s UK – used the test to assess voice, balance, walking and reaction time in people living with Parkinson’s. The results indicated that the test may be able to predict development of Parkinson’s symptoms up to 18 months before they occur. Researchers hope this will allow healthcare professionals to tailor a more personalised approach to the treatment of Parkinson’s. Christine Lo, clinical research fellow at the University of Oxford’s Oxford Parkinson’s Disease Centre, said: “The main driver for this study was to improve clinical care by finding better ways of predicting how Parkinson’s is likely to progress over time on an individual basis, as its course can vary greatly from person to…

Take part in a global Parkinson’s carers survey

The European Parkinson’s Disease Association (EPDA) is inviting carers from within the Parkinson’s community to take part in a survey aiming to shine a light on the physical, financial and emotional difficulties they face. The research – supported by French healthcare devices company Air Liquide – will be used to inform future campaigns and create valuable tools to help carers and the wider Parkinson’s community. Russell Patten, the secretary general of the EPDA, said: “Carers are such an important part of the Parkinson’s community – they provide the firm foundations that support their loved ones who are physically living with the condition. “However, carers’ needs and quality of life are sadly, all too often, overlooked; this can lead to devastating and lasting effects on the individual and the wider society.” The survey is open until 6 September 2019, and is available in English, French, German Italian, Danish, Dutch, Portuguese, Slovenian…

Scottish university reveals multimillion-pound Parkinson’s research partnership

The University of Dundee, UK, has announced a collaboration with South Korean pharmaceutical company Bukwang to develop a new treatment for Parkinson’s. Collaborating with researchers at the University of Oxford, UK, the university’s drug discovery unit (DDU) has found molecules that may reduce levels of a protein closely connected to the development of the condition. The new partnership will build on this existing relationship between the universities – and facilitate a further three-year Parkinson’s research programme which will move the molecules towards clinical development. Professor Paul Wyatt, head of the DDU, said: “Drug discovery for neurological disorders is especially challenging and an area where academia and industry need to be working together. “This project brings together the clinical and translational research expertise in Oxford with Dundee’s professional drug-discovery capabilities, allowing us to move one stage further towards a treatment.”

All fields required

First name*
Last name*
Email address*
Enter Email Confirm Email
Country of residence*
About me*
- I have Parkinson's disease
- I am a partner / carer / family / friend of someone who has Parkinson's
- I am a healthcare professional with an interest in Parkinson's
- I work for a Parkinson's disease organisation
- Other
CAPTCHA
*
- By proceeding you agree to our
Name
This field is for validation purposes and should be left unchanged.

Scottish university reveals multimillion-pound Parkinson’s research partnership

News

Author: Roisin McCormackPublished: 10 July 2019

Prep: Cook: Serves:

Last Month

Next Month

Share this story

Comments

Resources & Tools

New Parkinson’s app tracks symptoms

Interviews

“We want the world to walk with us,” says Parkinson’s Unity Walk leader

Advances

The huge potential of nanotechnology on new Parkinson’s treatments

Smartphone test predicts development of Parkinson’s symptoms, study says

Take part in a global Parkinson’s carers survey